why choose us

First received: July 17, 2023

Clinical Trial: Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Study Status: Completed

Recruit Status: RECRUITING

Condition: Acute Myeloid Leukemia

Study Type: INTERVENTIONAL


Official Title: A First-In-Human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy In Subjects With Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Brief Summary: The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921.

Read more